AVI Biopharma - der neue Highflyer ? - 500 Beiträge pro Seite

[cyberhai]

Hallo Leute !

AVI hatte am Freitag eine gute Performance hingelegt:

AVI BIOPHARMA INC (RT-ECN)
Symbol: AVII
Last Trade: 3.41 Oct 14
After Hours Change: Up 0.06 (1.79%)
Today`s Change: Up 0.71 (26.30%)
Bid: 3.40
Ask: 3.50

Derzeitige MK: 148.02 Mio Dollar

Der Langfrist-Chart:



Pipeline:

http://www.antivirals.com/devNeugene.html

Ich sehe hier aufgrund der guten Pipeline und der noch relativ niedrigen MK großes Potential.

Zudem wird AVI als Profiteur des "BioShield-Projektes" gehandelt. Testen in Kooperation mit dem Walter Reed Army Institut (WRAIR) die Wirkung seiner Antisense-Produkte gegen durch Flaviren ausgelöste Infektionskrankheiten zu denen auch Denguefieber und Gelbfieber zählen.

Letzte Meldungen:

http://biz.yahoo.com/bw/051014/145475.html?.v=1

http://biz.yahoo.com/ap/051014/avi_biopharma_neugene.html?.v…

http://biz.yahoo.com/bw/051003/35564.html?.v=1

Was haltet Ihr von dem Unternehmen?

Gruß Cyberhai

[Buddah]

14.10.2005 - 18:27
Biotech-Titel explodiert nach Studie

AVI Biopharma hat am Freitag erfolgreiche Ergebnisse aus einer Versuchsreihe an Tieren vermeldet. Danach wirkt der Antisense-Wirkstoff „Neugene“ des Unternehmens gegen den Ebola-Virus und den Marburg-Virus. Weiter ist Neugene offenbar in der Lage, den zellularen Mechanismus, der bei Kontakt mit den Giften Anthrax und Ricin tödlich wirkt, zu unterbrechen, wie das Unternehmen bekannt gab.

Anthrax oder auch Milzbrand und Ricin sind bereits verschiedentlich in militärischen Konflikten als chemische Kampfstoffe eingesetzt worden. Außerdem fürchten Sicherheitsexperten, daß Terroristen verstärkt auf diese Gifte zurückgreifen könnten. Ricin wird allerdings auch in der Krebstherapie zur Abtötung von Krebszellen eingesetzt. Die Studie von AVI wird teilweise vom US-Verteidigungsministerium finanziert.

AVI notiert derzeit bei 3,20$ (+18,52%).



ein äußerst interessantes Unternehmen.

gruss B.

[cyberhai]

Da könnte sich was anbahnen:

AVI BIOPHARMA INC (RT-ECN)
Symbol: AVII
Last Trade: 3.94 Nov 11
After Hours Change: Up 0.68 (20.86%)
Today`s Change: Up 0.80 (25.48%)
Bid: 3.40
Ask: 3.93
This is a free Real-Time ECN quote.

Gruß Cyberhai

[Lalo]

und zwar u.a. deshalb:

online.barrons.com/article/SB113175890284895503.html?mod=9_0…

[cyberhai]

Der Bericht gibt einen sehr guten Überblick, danke für den Link.

Ich glaube wir werden mit diesem Unternehmen noch viel Freude haben.

Gruß Cyberhai

[cyberhai]

AVI BioPharma Strengthens Scientific Advisory Board to Address Infectious Disease and Avian Influenza
Thursday November 17, 9:00 am ET
Three New Members Bring Specific Expertise in Emerging Infectious Diseases

PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 17, 2005--AVI BioPharma, Inc. (Nasdaq:AVII - News), today announced the addition of three new members to its Scientific Advisory Board to specifically address the potential emergence of avian influenza type H5N1.

Klaus O. Schafer, M.D., MPH, is the former deputy assistant to the Secretary of Defense for Chemical and Biological Defense. In this position, Dr. Schafer oversaw the $2.1 billion annual science, technology, research, development and acquisition program in the area of medical and nonmedical materials for chemical biological defense for the entire U.S. Department of Defense. Dr. Schafer worked closely with Congress, international partners and other federal agencies in this key position. A graduate of the U.S. Air Force Academy in Colorado Springs, Colo., he earned his doctor of medicine degree from the University of Iowa Medical School and a master of public health degree at the University of Texas Health Center. He currently serves as a founding partner of Tessarae, Inc., a manufacturer of equipment for the genomics marketplace.

David N. Gilbert, M.D., MACP, is a professor of medicine at Oregon Health & Science University (OHSU) and the William M. Garnjobst Chair of Graduate Medical Education and director of the Earle A. Chiles Research Institute for Providence Portland Medical Center. He is also the chief of the Infectious Diseases Program at the Providence Portland Medical Center. He formerly served as president of the following: the Infectious Diseases Society of America, the Oregon Chapter of the American College of Physicians, the Infectious Diseases Consortium of Oregon and the Infectious Diseases Society of Oregon. The University of Washington awarded Dr. Gilbert his undergraduate degree in zoology, and he received his medical degree at University of Oregon Medical School, where he graduated cum laude.

Thomas G. Voss, Ph.D., is currently an assistant professor in the department of microbiology and immunology at Tulane University School of Medicine. Before that, he was vice president and chief scientist of the Homeland Security and Infectious Disease Research Division for Southern Research Institute in Birmingham, Ala. He received his undergraduate degree from the University of Texas, and his Ph.D. in the field of microbiology and immunology from Tulane University School of Medicine. His current research involves developing animal models for testing vaccines, diagnostics and therapeutics against biodefense and emerging infectious diseases, including avian influenza. His previous research involves developing novel approaches for the treatment of anthrax, screening antiviral drugs against SARS coronavirus, and developing in vitro and animal models for testing the efficacy of innate immunity activators for prevention of infection and disease by viral, bacterial and other infectious agents.

"It is an honor to have these men join our Scientific Advisory Board," said Denis R. Burger, Ph.D., chief executive officer of AVI. "While the knowledge and experience each man brings is substantial in its own right, together they provide a tremendous body of expertise that we can benefit from as we move forward with our avian influenza drug development program."

AVI previously announced a NEUGENE® antisense drug development program targeting the influenza A (flu) virus, specifically genetic regions of the virus that are highly conserved between six viral subtypes that cause human disease. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2). Several NEUGENE antisense compounds have been efficacious in preclinical experiments and will now move to animal trials against H1N1 and H5N1.

"Using our targeted approach to blocking replication of the influenza virus, we believe that a single NEUGENE drug could be effective against a variety of influenza subtypes, not just the H5N1 variant of avian flu," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "By targeting regions of the viral genetic code that are common to all influenza A subtypes, we expect that our NEUGENE drug against avian flu will also be effective against the far more common influenza A virus H1N1, which kills an average of 35,000 Americans every year."


Gruß Cyberhai